Technological Advancements in Uncomplicated Urinary Tract Infection Treatment | Market Outlook
According to Future Market Insights, the Uncomplicated Urinary Tract Infection Treatment market demand is predicted to increase at a 10% CAGR from 2023 to 2033. The global market for Uncomplicated Urinary Tract Infection Treatment is anticipated to reach US$ 17 billion by the year 2033. The increasing awareness of the ailment, the growing elderly population, and the rising prevalence of UTIs all contribute to the market's growth.
The growing awareness of UTIs is one of the market's
primary drivers. More and more individuals are becoming aware of the symptoms
of UTIs and the significance of seeking immediate treatment as information
becomes more widely available online and through social media. This increases
demand for antibiotics and other therapies, boosting market growth.
The expanding geriatric population is another element
driving the market. People's risk of having UTIs increases as they age, and as
the world's population ages, so does the demand for UTI therapies. The number
of individuals aged 65 and more is anticipated to triple by 2050, reaching
roughly 1.5 billion, according to the United Nations.
Finally, the increasing prevalence of UTIs is fueling
market expansion. Factors such as rising diabetes rates, changes in sexual
behaviour, and increased use of catheters and other medical devices are all
contributing to an increase in UTI incidence. This is increasing the demand for
efficient medicines that can clear up UTIs fast and safely.
Key Takeaways from the Market Study
- The
global market for Uncomplicated Urinary Tract Infection Treatment is
predicted to develop at a 10% CAGR from 2023 to 2033.
- Retail
pharmacies are anticipated to account for 47% of the Uncomplicated Urinary
Tract Infection Treatment market in 2023.
- In
2023, North America is estimated to hold 48% of the market for Uncomplicated
Urinary Tract Infection Treatment.
- Europe's
Uncomplicated Urinary Tract Infection Treatment market is estimated to
account for 40% of the total by 2023.
- Retail
Pharmacies are expected to capture 47% of the market for Uncomplicated
Urinary Tract Infection Treatment, according to an FMI study.
Unlock
growth potential with industry expertise. Download your market sample report
now: https://www.futuremarketinsights.com/reports/sample/rep-gb-16923
Key Segments Profiled in the Uncomplicated
Urinary Tract Infection Treatment Industry Survey
Drug Class:
- Gepotidacin
- Probenecid
- Sulfonamide
- Tetracycline
- Nitrofuran
Distribution Channel:
- Hospital
Pharmacies
- Gynaecology
and Urology Clinics
- Retail
Pharmacies
- Online
Drug Stores
Comments
Post a Comment